InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,450.51
(
0.95%
)
US TECH 100
18,452.40
(
0.66%
)
Dow Jones
40,540.82
(
1.52%
)
Brent Oil
79.98
(
-1.91%
)
Bitcoin
67,465.24
(
2.55%
)
Post# of 3057
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

USMC56

Send PM Follow Ignore
Followers 5
Posts 746
Boards Moderated 0
Alias Born 09/20/2012

USMC56

Re: None

Tuesday, 10/23/2012 10:36:37 AM

Tuesday, October 23, 2012 10:36:37 AM

Post# of 3057
An FDA panel voiced safety concerns about Kynamro, which is a PS-ASO drug, and JMP Securities thinks that the concerns have the ability to affect Sarepta’s competitor in Duchene Muscular Dystrophy, GlaxoSmithKline’s PRO051. The firm also mentions that Sarepta’s drug is not a PS-ASO, and it keeps its Outperform rating on the stock
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent SRPT News
More SRPT News
InvestorsHub NewsWire

Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM

Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM

VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM

North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM

Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM

Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM

Start posting your company's news
Only $200 per official company press release!